Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dongcheng Biochemicals USA is the North American subsidiary of Yantai Dongcheng Pharmaceutical Group, a leading global manufacturer of biochemical active pharmaceutical ingredients (APIs). The company is recognized as one of the world's largest producers of heparin sodium and chondroitin sulfate, providing essential raw materials for the treatment of cardiovascular diseases and joint health. In addition to its API portfolio, the parent company has established a significant presence in the radiopharmaceutical industry through strategic acquisitions and internal development. The US office serves as a critical link for business development, regulatory affairs, and supply chain management for the American market. Dongcheng continues to expand its footprint in nuclear medicine, focusing on both diagnostic and therapeutic radiopharmaceuticals.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dongcheng Biochemicals USA.